Tirzepatide vs GLP-1RAs and IBD risk

A retrospective US study published online on 10 September 2026 in the journal Intestinal Research reported that patients with inflammatory bowel disease (IBD) who were prescribed tirzepatide had a lower adjusted risk of needing intravenous steroids over 18 months than matched patients prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist^[1]. Researchers from Virginia Commonwealth University, led by Kinjal Patel, compared 3,042 propensity-matched patient pairs and found an adjusted hazard ratio of 0.81 for IV steroid use favouring tirzepatide^[1]. The study is observational, not a clinical trial, and it does not show that either drug treats IBD.

What the study found

The researchers drew on a national, multi-institutional US health-record network and matched adults who had a diagnosis of IBD and a prescription for either tirzepatide or a GLP-1 receptor agonist such as semaglutide, liraglutide, or dulaglutide. Matching used propensity scores intended to balance the two groups on age, sex, IBD subtype, and other recorded health factors. Over 18 months of follow-up, the tirzepatide group showed a lower adjusted hazard of needing intravenous steroids (aHR 0.81, 95% CI 0.68 to 0.94) and a lower adjusted hazard on a composite measure combining IV steroid use with intestinal surgery (aHR 0.86, 95% CI 0.73 to 0.97)^[1].

A subgroup limited to patients with ulcerative colitis showed a similar pattern for IV steroid use (aHR 0.82, 95% CI 0.69 to 0.97). The study reported no statistically meaningful difference between the two groups on intestinal surgery rates, emergency department visits, or hospitalization when those outcomes were measured on their own rather than folded into the composite^[1]. In plain terms: one narrow slice of health-system utilization, the need for IV steroids, differed between groups. Most of the other outcomes tracked did not.

This is not a study of an IBD treatment

Nothing about this study tested tirzepatide or any GLP-1 receptor agonist as a treatment for IBD. The patients in both groups already had IBD, and they were prescribed these drugs for the reasons doctors normally prescribe them: type 2 diabetes or weight management. Tirzepatide's US label and its EU marketing authorisation both cover glycaemic control in type 2 diabetes, cardiovascular risk reduction in adults with type 2 diabetes, and weight management; neither mentions inflammatory bowel disease, Crohn's disease, or ulcerative colitis as an approved use^[2][3]. The study authors were asking a narrower and more useful question: among people who already have IBD and are also being treated with one of these drug classes for an unrelated condition, does the choice of drug class track with different IBD-related health-system contact. That is a different question from whether either drug treats or improves IBD.

Why researchers looked at this comparison

People living with IBD have elevated rates of obesity and type 2 diabetes, so a meaningful share of IBD patients already take a GLP-1 receptor agonist or tirzepatide for those unrelated conditions. That overlap is what makes a comparison between drug classes possible using existing health records, without needing a dedicated trial. Separate laboratory and mechanistic work has looked at how incretin-pathway signalling interacts with gut and immune tissue, which is part of the background interest in whether the two drug classes might differ here. This study did not test or confirm any mechanism. It compared outcomes in existing records and reported an association, not a cause.

What this study does not show

The design is retrospective and observational, which the authors themselves flagged, writing that "prospective studies are warranted to validate these results and explore underlying mechanisms"^[1]. A few limitations matter for how much weight to put on the finding. First, confounding by indication: doctors may choose tirzepatide over an older GLP-1 receptor agonist for reasons tied to a patient's overall health picture, and propensity matching narrows that gap without closing it completely. Second, the outcomes measured are health-system contact points, IV steroid orders, ED visits, hospital admissions, surgery, not direct measures of gut inflammation such as endoscopy findings, calprotectin levels, or standardized disease-activity scores. Third, the follow-up window is 18 months, which is short for a chronic disease that can wax and wane over years. And fourth, this is a single country's health-record data, so it says nothing about how the pattern might look under different prescribing habits or healthcare systems elsewhere.

What this means for readers

If you have IBD and take tirzepatide or a GLP-1 receptor agonist for diabetes or weight management, this study is not a reason to change anything on your own. It is one early, hypothesis-generating data point from a retrospective comparison, not a treatment recommendation and not a signal that either drug is being newly approved or studied for IBD itself. Any question about switching medications, or about what your IBD activity and your metabolic health mean for each other, belongs in a conversation between you, your gastroenterologist, and whichever clinician manages your diabetes or weight-management prescription.

The more durable takeaway is about the evidence itself. A single retrospective comparison with a modest effect size, published the same week it was reported, is a starting point for further research, not a settled answer. Readers tracking the broader tirzepatide and GLP-1 literature should expect this finding to either firm up or fade as prospective data arrives.